U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory EnvironmentGLEN ALLEN, Va.,…
The Investment is part of BrainsWay’s ongoing strategy to acquire minority positions in leading U.S. mental health providers to help…
After a successful pilot, Dismas Charities partners with The Change Companies to bring individualized, digital-first programming to justice-involved individuals. CARSON…
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4…
~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed,…
DEA Administrator Terrance Cole has also signaled a tough line: "Everybody knows my stance on marijuana after 30 plus years…
We're Out of Time Podcast Host & Addiction Recovery Expert Richard Taite Endorses Bereaved Parents' Nationwide, In-School Fentanyl Prevention Effort…
GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage…
Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment…
- Revenue of $1.9 Million consistent with the year-ago period- Revenue led by Population Health's growth up 197% compared to…